2,778 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC bought a new stake in shares of Insulet Co. (NASDAQ:PODD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,778 shares of the medical instruments supplier’s stock, valued at approximately $725,000.

Several other institutional investors also recently bought and sold shares of PODD. SBI Securities Co. Ltd. purchased a new position in shares of Insulet in the fourth quarter valued at approximately $36,000. SRS Capital Advisors Inc. boosted its position in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares during the period. Friedenthal Financial acquired a new position in shares of Insulet in the fourth quarter worth $57,000. Assetmark Inc. increased its position in shares of Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after acquiring an additional 246 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of Insulet by 117.3% in the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $72,000 after acquiring an additional 149 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Stifel Nicolaus boosted their target price on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Raymond James reaffirmed an “outperform” rating and issued a $328.00 target price (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Citigroup boosted their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Piper Sandler raised their price objective on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Finally, TD Cowen boosted their target price on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insider Activity

In other news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now owns 3,231 shares of the company’s stock, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Down 1.6 %

PODD stock opened at $246.80 on Friday. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market cap of $17.33 billion, a price-to-earnings ratio of 42.63, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. The company has a fifty day moving average price of $264.04 and a 200 day moving average price of $260.72.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Sell-side analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.